| scholarly article | Q13442814 |
| P50 | author | Dennis Wolf | Q56949433 |
| Melanie Vassallo | Q60726250 | ||
| Holger Winkels | Q84185642 | ||
| Kouji Kobiyama | Q87757884 | ||
| Klaus F. Ley | Q89016809 | ||
| P2093 | author name string | Jacqueline Miller | |
| Hong Pei | |||
| Takayuki Kimura | |||
| Jessica Mitzi | |||
| P2860 | cites work | Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice | Q24293865 |
| Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults | Q27009478 | ||
| Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants | Q29615635 | ||
| Regulatory T cells and immune tolerance | Q29616864 | ||
| Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen. | Q30371719 | ||
| Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease | Q31135767 | ||
| Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences | Q31135771 | ||
| LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis | Q31807216 | ||
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. | Q34043472 | ||
| Efficacy and safety of alirocumab in reducing lipids and cardiovascular events | Q34467233 | ||
| IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. | Q34583514 | ||
| Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases | Q34615216 | ||
| Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis | Q34737721 | ||
| The self-obsession of T cells: how TCR signaling thresholds affect fate 'decisions' and effector function | Q35143413 | ||
| Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes | Q35184223 | ||
| Type 1 regulatory T cells (Tr1) in autoimmunity | Q35226496 | ||
| The immune epitope database (IEDB) 3.0. | Q35254745 | ||
| Vaccination to modulate atherosclerosis | Q35600876 | ||
| Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes | Q35683291 | ||
| Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization | Q36402763 | ||
| Mutant MHC class II epitopes drive therapeutic immune responses to cancer | Q36817092 | ||
| Advances in the development of vaccines for Alzheimer's disease | Q36965988 | ||
| Pleiotropic effects of statins. - Basic research and clinical perspectives -. | Q37252114 | ||
| IFN-gamma potentiates atherosclerosis in ApoE knock-out mice | Q37368296 | ||
| Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. | Q37415733 | ||
| The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination | Q37421379 | ||
| T-Cells Specific for a Self-Peptide of ApoB-100 Exacerbate Aortic Atheroma in Murine Atherosclerosis | Q37660865 | ||
| Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice. | Q37848119 | ||
| AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types | Q37851958 | ||
| Active immunotherapy for chronic diseases | Q38082233 | ||
| Therapeutic vaccines for cancer: an overview of clinical trials | Q38227030 | ||
| Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease. | Q38368422 | ||
| Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults | Q38506829 | ||
| A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases | Q38660995 | ||
| AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial | Q39447289 | ||
| Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression | Q39601696 | ||
| Deaths: Leading Causes for 2014. | Q39633281 | ||
| Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. | Q39975880 | ||
| Selective events in T cell development | Q40661180 | ||
| ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions | Q43140494 | ||
| Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice | Q43455128 | ||
| Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes | Q44011973 | ||
| Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis | Q45232086 | ||
| A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity | Q45409539 | ||
| Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes | Q46133692 | ||
| Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. | Q46272404 | ||
| Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice | Q46452772 | ||
| Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells | Q46473311 | ||
| Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice | Q46804215 | ||
| Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice | Q47392093 | ||
| Vaccination with Antigen Combined with αβ-ATP as a Vaccine Adjuvant Enhances Antigen-Specific Antibody Production via Dendritic Cell Activation. | Q51725278 | ||
| ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. | Q51887546 | ||
| Regulatory CD4+ T Cells Recognize MHC-II-Restricted Peptide Epitopes of Apolipoprotein B. | Q52626860 | ||
| FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. | Q53037689 | ||
| DNA released from dying host cells mediates aluminum adjuvant activity | Q56897591 | ||
| Natural regulatory T cells control the development of atherosclerosis in mice | Q58149268 | ||
| Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis | Q74290884 | ||
| Atheroprotective effect of adjuvants in apolipoprotein E knockout mice | Q80952585 | ||
| Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine | Q82652342 | ||
| Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis | Q82956532 | ||
| Production of a plant-derived immunogenic protein targeting ApoB100 and CETP: toward a plant-based atherosclerosis vaccine | Q87629622 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1580-1587 | |
| P577 | publication date | 2018-08-12 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | A clinically applicable adjuvant for an atherosclerosis vaccine in mice | |
| P478 | volume | 48 |
Search more.